Lucia Parlati
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Year:
2026
Background and Aims Early assessment of hepatocellular carcinoma (HCC) risk could improve long‐term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not easily implementable. We developed easy‐to‐use HCC predictive scores based on behavioural and routine bio‐clinical data in people with chronic HBV infection. Methods Eight‐year follow‐up data was analysed from people with chronic HBV infection enrolled in the French ANRS CO22 HEPATHER cohort. Patients were randomly split into two samples (training/testing). A multivariable Cox model for time to HCC was estimated on the training sample. The HCC predictive score was computed by summing the points assigned to model predictors, normalising their coefficients over a 10‐year age increment, and rounding to the nearest integer. The Youden index identified the score's optimal risk threshold. Comparisons with existing predictive scores were performed on the testing sample. Results In the study population ( N = 4370; 63% of men; 65% of < 50 years old), 56 HCC cases occurred during 25,900 follow‐up person‐years. Two HCC predictive scores were defined: SADAPTT (daily soft drink consumption, age, hepatitis Delta infection, unhealthy alcohol use, platelet count, heavy tobacco smoking, and HBV treatment) and ADAPTT (the same predictors except for daily soft drink consumption), with ranges 0–13 and 0–14, respectively, and values ≥ 3 indicating a high HCC risk. Their performances were similar to existing scores. Conclusions We developed two effective behaviour‐based HCC predictive scores, implementable in many settings, including primary care and decentralised areas. Further studies are needed to validate these scores in other datasets.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Background Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV mutations. FMF patients can experience liver involvement, potentially leading to cirrhosis. Objectives This study aimed to evaluate liver involvement in FMF patients at a French tertiary centre for adult FMF. Methods We conducted an observational study with FMF patients displaying 2 pathogenic MEFV mutations at the National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA) in Paris and included in the JIR cohort. MEFV heterozygous patients and those with other liver disease causes were excluded. Results Among 533 FMF patients 12.4% had chronic liver abnormalities, with 30% who developed cirrhosis 54 years [36–57] in median after disease onset. Forty‐seven per cent were colchicine resistant, and 41% received interleukin‐1 inhibitors. Cirrhotic patients experienced delayed hepatopathy diagnosis, prolonged FMF diagnosis delay and late‐onset treatment initiation compared to those with only liver function test abnormalities. Colchicine resistance and interleukin‐1 inhibitor use were more common in cirrhotic patients. Body mass index and AA amyloidosis rates did not differ significantly between groups. Twenty‐one patients had undergone liver biopsies including 14 cirrhotic patients revealing steatohepatitis in 12 cases and probable steatohepatitis in 4. Other lesions, like iron overload and sinusoidal dilatation, were sporadically observed. Conclusion FMF patients are at risk of chronic liver disease. Regular liver function monitoring is crucial, particularly in case of persistent inflammation, due to the risk of progression to cirrhosis and its associated morbidity and mortality.
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (7)
Marco Dioguardi Burgio
Université Paris Cité
Fabien Zoulim
Université Claude Bernard Lyon 1
Anita Paisant
-
Sophie Georgin-Lavialle
Full professor of internal medicine
Sorbonne Université
Marion Regnier
Chargée de Recherche
Centre National de la Recherche Scientifique (CNRS)
Vincent Mallet
Professor
Université Paris-Saclay
Jérémie Gautheron
INSERM
Make your next move.
Prepare your application
Review drafts before you send them.